- Home
- MCVT vs EVAX Comparison
MCVT vs EVAX Comparison
Compare MCVT & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCVT
- EVAX
- Stock Information
- Founded
- MCVT 2007
- EVAX 2008
- Country
- MCVT United States
- EVAX Denmark
- Employees
- MCVT N/A
- EVAX N/A
- Industry
- MCVT Finance Companies
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCVT Finance
- EVAX Health Care
- Exchange
- MCVT Nasdaq
- EVAX Nasdaq
- Market Cap
- MCVT 13.2M
- EVAX 14.3M
- IPO Year
- MCVT N/A
- EVAX 2021
- Fundamental
- Price
- MCVT $1.96
- EVAX $1.55
- Analyst Decision
- MCVT
- EVAX Strong Buy
- Analyst Count
- MCVT 0
- EVAX 2
- Target Price
- MCVT N/A
- EVAX $11.00
- AVG Volume (30 Days)
- MCVT 9.6K
- EVAX 27.9K
- Earning Date
- MCVT 11-12-2024
- EVAX 10-31-2024
- Dividend Yield
- MCVT N/A
- EVAX N/A
- EPS Growth
- MCVT N/A
- EVAX N/A
- EPS
- MCVT 0.05
- EVAX N/A
- Revenue
- MCVT $3,234,265.00
- EVAX $3,295,000.00
- Revenue This Year
- MCVT N/A
- EVAX $4,845.21
- Revenue Next Year
- MCVT N/A
- EVAX $30.30
- P/E Ratio
- MCVT $39.49
- EVAX N/A
- Revenue Growth
- MCVT N/A
- EVAX N/A
- 52 Week Low
- MCVT $1.86
- EVAX $1.59
- 52 Week High
- MCVT $3.88
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- MCVT 41.63
- EVAX 20.33
- Support Level
- MCVT $1.88
- EVAX $1.59
- Resistance Level
- MCVT $2.20
- EVAX $2.63
- Average True Range (ATR)
- MCVT 0.09
- EVAX 0.22
- MACD
- MCVT 0.00
- EVAX -0.10
- Stochastic Oscillator
- MCVT 25.00
- EVAX 3.97
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.